EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Outcomes for recurrent or metastatic head and neck cancer by HPV status: a systematic review and meta-analysis

Jong Chul Park, Geun Hee Ye, Ross Merkin iD, Thomas Roberts

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf043 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Oncologist, 2025. Verfasst von Jong Chul Park und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, United States. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Papillomavirus Infections, Neoplasm Recurrence, Local, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Human papillomavirus (HPV)-positive (HPV+) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) exhibits distinct clinical behavior compared with HPV-negative (HPV−) R/M HNSCC. However, most studies reference historical efficacy benchmarks from cohorts combining HPV+ and HPV− R/M HNSCC for comparison with the efficacy of novel therapeutics. This analysis aims to assess differential outcomes specific to HPV+ and HPV− R/M HNSCC to reflect HPV-associated prognostic considerations.

Methods

Studies from March 2006 to June 2024 were searched. All therapeutic trials in R/M HNSCC that reported outcomes by HPV status were included. Meta-analyses were conducted to evaluate overall survival (OS) as the primary outcome of interest, objective response rate, and progression-free survival as secondary outcomes. Weighted averages were used to estimate the outcome measures for each group.

Results

A total of 10 studies representing 3509 patients met the inclusion criteria. For the first-line setting, the weighted average OS estimates were 20.7 months (95% CI, 19.4-21.9) and 12.2 months (95% CI, 11.9-12.4) for HPV+ and HPV− HNSCC, respectively. For the second or later line treatment setting, the weighted average OS estimates were 11.1 months (95% CI, 10.2-12.1) and 8.3 months (95% CI, 7.9-8.6) for HPV+ and HPV− subgroups, respectively.

Conclusion

Our analysis demonstrated a clinically meaningful difference between in the HPV+ and HPV− R/M HNSCC populations. These findings support the establishment of HPV-specific outcome benchmarks, which are essential for prognostic awareness, optimizing therapeutic development, and accurately interpreting clinical trial data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Head and Neck NeoplasmsPapillomavirus InfectionsNeoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and NeckPapillomaviridaeHumansPrognosisNeoplasm Metastasis

Stichwörter der Autor:innen

head and neck cancerhuman papillomavirussurvival outcome

Autor:innen und Institutionen

  • Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, United States.
  • Department of Medicine, Harvard Medical School, Boston, MA 02115, United States.
  • Department of Medicine, CHA University School of Medicine, Pocheon, Gyeonggi-do, 11160, South Korea.

ORCID-Profile: Ross Merkin

Zitieren

APA

Park, J. C., Ye, G. H., Merkin, R., & Roberts, T. (2025). Outcomes for recurrent or metastatic head and neck cancer by HPV status: a systematic review and meta-analysis. The Oncologist. https://doi.org/10.1093/oncolo/oyaf043

Vancouver

Park JC, Ye GH, Merkin R, Roberts T. Outcomes for recurrent or metastatic head and neck cancer by HPV status: a systematic review and meta-analysis. The Oncologist. 2025. doi:10.1093/oncolo/oyaf043

BibTeX
@article{Park2025,
  author = {Park, Jong Chul and Ye, Geun Hee and Merkin, Ross and Roberts, Thomas},
  title = {Outcomes for recurrent or metastatic head and neck cancer by HPV status: a systematic review and meta-analysis},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf043}
}
Kostenlos starten →